You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Human Epidermal Growth Factor Receptor 3

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

Recruiting
  • Locally Advanced or Unresectable Metastatic Breast Cancer
  • Stage IV Breast Cancer
  • Sacituzumab Govitecan-hziy
  • +3 more
  • Marietta, Georgia
  • +1 more
Apr 21, 2023

Breast Tumors Trial in Chuo Ku, Koto-Ku (H3B-6545, Antihistamine)

Active, not recruiting
  • Breast Neoplasms
  • Chuo Ku, Japan
  • +1 more
Dec 19, 2022

Primary Breast Cancer Trial (SPECT)

Not yet recruiting
  • Primary Breast Cancer
  • (no location specified)
Jun 19, 2023

Breast Cancer Trial in Orange City (ARV-471 (PF-07850327), Palbociclib, Letrozole)

Recruiting
  • Breast Cancer
  • ARV-471 (PF-07850327)
  • +2 more
  • Orange City, Florida
    Mid Florida Hematology and Oncology Center
Jun 8, 2023

Recurrent/Advanced Gastric Cancer Trial in Seoul (Chemotherapy)

Not yet recruiting
  • Recurrent/Advanced Gastric Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Aug 22, 2022

Breast Cancer Female Trial in Tomsk ([99mTc]Tc-G3-(G3S)3C)

Enrolling by invitation
  • Breast Cancer Female
  • Tomsk, Russian Federation
    Olga
Jun 19, 2023

Metastatic Breast Cancer Trial in Dallas (DB-1303, Capecitabine, Paclitaxel)

Not yet recruiting
  • Metastatic Breast Cancer
  • Dallas, Texas
    Texas Oncology - Baylor Charles A. Sammons Cancer Center
Aug 25, 2023

99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast

Enrolling by invitation
  • Breast Cancer Female
  • 99mTc-DARPinG3 SPECT/CT
  • Tomsk, Russian Federation
    Russia Tomsk NRMC
Jan 23, 2023

Breast Tumors, Breast Cancer, Adenocarcinomas Trial run by the NCI (AdHER2/neu DC Vaccine)

Completed
Has Results
  • Breast Neoplasms
  • +3 more
  • Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 12, 2022

Metastatic Breast Cancer Trial in Japan, United States (Patritumab Deruxtecan)

Active, not recruiting
  • Metastatic Breast Cancer
  • Patritumab Deruxtecan
  • Newnan, Georgia
  • +25 more
Dec 5, 2022

Breast Cancer Trial in Shanghai (HS-10352 combined with fulvestrant (Stage 1), HS-10352 combined with fulvestrant (Stage 2))

Recruiting
  • Breast Cancer
  • HS-10352 combined with fulvestrant (Stage 1)
  • HS-10352 combined with fulvestrant (Stage 2)
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 15, 2022

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

Not yet recruiting
  • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
  • PERT-IJS plus trastuzumab, carboplatin and docetaxel
  • Perjeta plus trastuzumab, carboplatin and docetaxel
  • (no location specified)
Sep 21, 2023

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in

Not yet recruiting
  • Anatomic Stage II Breast Cancer AJCC v8
  • +3 more
  • Biospecimen Collection
  • +7 more
  • Portland, Oregon
    SWOG
Sep 27, 2023

Molecular Imaging in HER2-positive Breast Cancer During

Enrolling by invitation
  • HER2-positive Breast Cancer
  • Female
  • Tomsk, Russian Federation
  • +1 more
Jun 7, 2022

A NIS of Alpelisib in Combination With Fulvestrant in

Not yet recruiting
  • Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
  • Alpelisib
  • Fulvestrant
  • (no location specified)
Aug 9, 2022

Breast Cancer Female Trial in Tomsk (99mTc-ADAPT6, 99mTc-DARPinG3)

Recruiting
  • Breast Cancer Female
  • Tomsk, Russian Federation
    Tomsk NRMC
May 12, 2022

Breast Cancer Trial in Sarasota, Nashville (AC699)

Recruiting
  • Breast Cancer
  • Sarasota, Florida
  • +1 more
Jan 3, 2023

Breast Cancer Invasive Trial (pyrotinib)

Not yet recruiting
  • Breast Cancer Invasive
  • (no location specified)
Jun 18, 2023

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Ocala, Florida
    Ocala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023

Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer Trial (Trastuzumab,

Recruiting
  • Brain Metastases
  • +2 more
  • Saint Louis, Missouri
  • +1 more
Nov 8, 2022

Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T

Not yet recruiting
  • Recurrent Glioblastoma
  • Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
  • (no location specified)
Apr 4, 2023

Primary Breast Cancer Trial in Tomsk (SPECT)

Completed
  • Primary Breast Cancer
  • Tomsk, Russian Federation
    TomskNRMC
Oct 4, 2021

Breast Cancer Trial in Beijing, Zhengzhou, Changsha (EG017)

Not yet recruiting
  • Breast Cancer
  • Beijing, Benjing, China
  • +2 more
Dec 30, 2022